SALA DE PRENSA DE RENOWN

Renown Health and the University of Nevada, Reno School of Medicine give the gift of early diagnosis and disease prevention this holiday season.   With the season of giving upon us, give yourself the gift of health. The Renown Institute for Health Innovation (IHI) and the University of Nevada, Reno School of Medicine (UNR Med) are excited to offer a free Enhanced Liver Fibrosis (ELFTM) test to patients at risk for a common type of liver disease, e.g. metabolic and nonalcoholic steatohepatitis (M/NASH), and who enroll or are currently enrolled in the Healthy Nevada Project. The ELF Test is an FDA (Food and Drug Administration) approved non-invasive test to help identify people most at risk for liver scarring, e.g. cirrhosis, and allows doctors to intervene before irreversible damage occurs. If undetected and untreated, M/NASH can result in liver cirrhosis which could require liver transplantation or lead to death. This test is important as the symptoms of M/NASH can be silent or non-specific, making it difficult to diagnose.  “There are currently more than 11,000 people across the U.S. on the national liver transplant waiting list, and with the heightened prevalence of NAFLD and M/NASH, this number is projected to keep rising; however, with research such as the ELF Test at our disposal, we are continuing to find ways to improve the health of those at risk for advanced liver disease,” said Bill Plauth, MD, Chief Medical Officer for Renown Health and Associate Dean of Clinical Affairs at UNR Med. “We encourage our community to participate in this early risk detection. Through this sophisticated, noninvasive, blood test, our physicians and Advanced Practice Providers can better evaluate liver fibrosis to help those affected and enable researchers to improve the prevention and treatment of nonalcoholic liver disease as a whole.”  This liver health-focused sub-study of the Healthy Nevada Project seeks to enhance the understanding of both NAFLD and M/NASH and to help inform the development of treatment options for these conditions, as few currently exist. “Providing access to cutting-edge innovations such as the ELF Test is critical for both participants and the physicians and advanced practice providers that care for them.” said Joseph Grzymski, PhD, principal investigator of the Healthy Nevada Project and the Liver Disease Study and research professor at UNR Med. Those interested in determining their risk for M/NASH and its progression are encouraged to enroll in the Metabolic & Nonalcoholic Steatohepatitis study. Those who have consented and participated in the M/NASH research will be eligible and contacted with more information on how to receive the ELF Test. The Renown IHI is also happy to connect with physicians and Advanced Practice Providers interested in having their patients enroll in the Healthy Nevada Project and join the study. For members of the community who would like more information and learn how to enroll, please contact the Renown IHI at RenownIHI@renown.org or (775) 982-6914 to be connected to a Genomic Representative. About the ELF™ Test  The ELF Test is a noninvasive blood test that can quickly identify which patients are at an elevated risk for developing cirrhosis and other liver-related clinical events (LREs). In contrast to standard liver enzyme tests that reflect liver damage that has already occurred, the ELF Test combines three serum direct biomarkers of active fibrosis. The ELF Test algorithm measures each of these biomarkers to create an ELF score, which can be used as an aid to assess the risk for future disease progression. Doctors may use this ELF score to help evaluate if a patient requires increased medical care and monitoring for their condition. Individuals interested in determining their risk for NASH and its progression are encouraged to enroll in the Nonalcoholic Steatohepatitis Liver Disease Genome Atlas study. Those who have already consented and participated in the study will be contacted with more information on how to receive an ELF blood test. Para obtener más información o para inscribirse, comuníquese a la casilla de correo RenownIHI@renown.org o al teléfono (775) 982-6914. In the U.S., the ELF Testing Service is available from Brio Clinical, Inc., a CLIA-certified laboratory offering specialized testing throughout the United States. Brio Clinical is regulated under CLIA as qualified to perform high complexity testing.

Leer más About Give the Gift of Health This Season with ELF Testing

Get to know Renown’s new CEO in his letter to employees and care providers. Today marks Dr. Brian Erling’s first day as Renown Health’s President & CEO. Dr. Erling sent the following letter and this video to Renown’s employees and care providers. We are pleased to share it with our community. Hello! Today marks my first day as your Renown Health President and CEO, so I thought I would kick off the occasion with a note. Throughout the interview process, I have been beyond impressed with the passion and purpose demonstrated by all who I have met, and I am overwhelmed with gratitude for the warm welcome that we have received. I look forward to meeting each and every one of you, but it may take some time to get to all 7000 of you, so I thought I would share some information not included in the initial announcement. A bit about where I come from and what I believe, which informs how I approach leadership. Healthcare has been my passion for as long as I can remember. I grew up in Minnesota and started my healthcare career as a nursing assistant during high school, and then as a monitor tech during college. After medical school and training, I went on to spend the next dozen years in the ED of a Level I trauma center in west Denver. I met my wife, Jessica, while attending medical school in Baltimore. She was working as a nurse in the surgical ICU and I was smitten. I offered to help her with a 3 am turn and bed linen change for our trauma patient, and the rest was history. We have three kids ages 17-22. I may wear a suit, but first and foremost I am a husband, father, clinician and a caregiver. Over the last 20+ years, I have worked my fair share of nights, weekends, and holidays, and I know the sacrifice you and your families make to care for our community. I will never take it for granted. I have been the sole provider covering a busy night shift, and I know that the trust and collaboration with your immediate team matters more than anything I am putting in this email. In fact, being part of a high performing, mission-driven team is my number one motivation. It’s what gets me up in the morning and why I work in healthcare. I have provided clinical leadership for a large, regional health system and understand that quality, safety, and innovation comes from the people doing the work, not from a corporate office. But you also need strong managers and leaders to facilitate and prioritize the work, and to provide support and inspiration. I view our greatest resource to be our people (each of you). Fancy robots, imaging equipment, etc. are essential, but they are not why our patients choose us. They come for your brand of hometown, trusted care. I am very excited about the new partnership with Renown and the University of Nevada, Reno School of Medicine. While still in its infancy, it provides the platform for us to be the center for training, research, and tertiary care for the region (and beyond). Most health systems would love to have their own health plan. The reality is that you cannot meaningfully improve the health of the population without managing value and risk. We are fortunate to have Hometown Health as part of Renown Health, and in our community, and I am excited to work with them to fulfill the mission of the organization. I have worked in for-profit and not-for profit healthcare. Renown is unique in the market as the only nonprofit health system in the market. What that means is that we invest every penny earned back into caring for our community. We don’t send money to shareholders in California or Pennsylvania, we invest it right here in Nevada. That is the kind of organization that I want to work for and where I want my family to get care. Some of you may have noticed that healthcare leaders have an impressively short half-life. I recall not being terribly impressed with one of our hospital leaders early in my career, and one of my senior partners told me to “just wait, he’ll be gone in a year or two.” She was correct. In fact, I had five CEOs in the time I was practicing in Denver. It’s difficult to create and move an organization toward a unified vision when your leader changes every few years. As my track record will support, this is not my style. I have been in Colorado for over twenty years and now look forward to making Reno and Renown my home for years to come. We are in an unprecedented time in healthcare, as all U.S. health systems are experiencing skyrocketing expenses and insufficient revenue growth. Renown is not immune to these pressures, but we are well positioned in the market to weather the storm. By focusing on continuous clinical and operational improvement, Renown will continue to set the gold standard for community health system performance. I appreciate you taking the time to read this message. I look forward to meeting with and learning from all of you. When you see me in the hallway or out and about, please come up and say hello. The work we do is hard, but I try to make it fun when I can, and I definitely like to play hard outside of work. I have been snowboarding the Rockies for the last 20 years and am excited to ride some new trails. When I see you around, let me know if you have some favorite terrain to recommend. Here, at your side, and ready to FIGHT THE GOOD FIGHT! Brian Erling, MD, MBA President & CEO, Renown Health About Renown Health Renown Health is Nevada’s largest, locally governed, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. Con una fuerza laboral diversa de más de 7,000 empleados, Renown ha fomentado una cultura de excelencia, determinación e innovación de larga data. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the locally owned not-for-profit insurance company, Hometown Health. Actualmente, Renown está inscribiendo participantes en el estudio genético de salud poblacional basado en la comunidad más grande del mundo, el Healthy Nevada Project®.

Leer más About New CEO of Renown Health, Dr. Brian Erling, Shares Thoughts With Physicians And Colleagues on His First Day

Healthcare physician CEO with 20 years of experience to lead northern NV’s largest health system on Nov. 14, 2022 Renown Health has selected Brian Erling, MD, MBA, as the health system’s next CEO and president, effective 14 de noviembre de 2022. Dr. Erling is a seasoned healthcare executive with over 20 years of experience leading teams in diverse healthcare settings, including locally governed, not-for-profit hospitals and integrated health systems; physician practices; publicly traded healthcare companies; and private equity-backed healthcare ventures Dr. Erling is a former healthcare executive with Centura Health in Denver having served since 2016 in positions of increasing and major responsibility, including Chief Medical Officer, Senior Vice President & Chief Clinical Officer and most recently as President & CEO of Penrose-St. Francis Health Services which represents the Colorado Springs market for Centura Health and includes Penrose Hospital, St. Francis Hospital, and St. Francis Hospital-Interquest slated to open in July 2023. During his tenure, he served as Senior Vice President and Chief Clinical Officer, responsible for providing clinical leadership to 17 hospitals and 21,000 caregivers. A highly experienced emergency medicine physician, Dr. Erling has long been a leader in quality improvement and is a Baldrige Executive Fellow through the National Institute of Standards and Technology (NIST). Dr. Erling also oversaw a partnership between Penrose-St. Francis Health and the University of Colorado, Colorado Springs through the William J. Hybl Sports Medicine and Performance Center, a first-of-its-kind facility, designed with intentional collaboration spaces for student and faculty education and research that opened in 2020. Prior to joining Centura Health, Dr. Erling served as President of the Alliance Group, a subsidiary of Envision Healthcare. He was also a founding partner of the Apex Emergency Group, PC in Denver and has served as the Denver medical director for American Medical Response. Dr. Erling received his Bachelor of Science in biology from Drake University in Des Moines, Iowa; his Medical Doctorate from Johns Hopkins University in Baltimore; and his Master of Business Administration from the University of Colorado in Denver. He completed his residency in emergency medicine at the University of Virginia in Charlottesville. Dr. Erling is board certified through the American Board of Emergency Medicine. “Dr. Erling is a collaborative and relational leader who brings a depth of experience to Renown Health and to our community. He is a healthcare executive focused on clinical quality and safety, an approachable servant-leader who inspires others with emotional intelligence and relationship skills; and a seasoned strategist with experience and discipline around healthcare operations, finance, and a proven ability to advance performance,” said Adam Kramer, chair of Renown Health’s Board of Directors. “Dr. Erling has the exceptional leadership skills, experience, background, vision and a commitment to Renown’s mission, values, and culture. We are happy to have Dr. Erling leading Renown Health and know he, his wife Jessica and family will be warmly welcomed to our northern Nevada community.” “I am so excited to be joining Renown Health at this important time. Healthcare and our economy are in the midst of a major transformation, and Renown Health is very well positioned for the future,” Dr. Erling said. “Our ongoing success will hinge on our ability to establish positive and productive relationships, maintain high-quality patient clinical outcomes and experiences, reduce healthcare costs, encourage innovation and improve access and affordability for patients and members.” Dr. Erling will assume the full duties of president and CEO on 14 de noviembre de 2022. Dr. Thomas Graf, who has served as interim CEO and Sy Johnson MBA, who has served as interim president, will both work with Dr. Erling to ensure a smooth transition of responsibilities. Dr. Graf will continue to serve as Chief Clinical and Quality Officer for Renown Health and Senior Associate Dean for Clinical Affairs at the University of Nevada, Reno School of Medicine. Sy Johnson, MBA, will continue to serve as Chief Operations Officer and Chief of Staff for Renown Health. Dr. Erling and his wife Jessica have three adult children and enjoy making the most of the great outdoors. About Renown Health Renown Health is Nevada’s largest, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe, and northeast California. With a diverse workforce of more than 6,500 employees, Renown has fostered a longstanding culture of excellence, determination, and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the locally owned not-for-profit insurance company, Hometown Health. Renown is currently enrolling participants in a community-based genetic population health study, the Healthy Nevada Project®.

Leer más About Brian Erling, MD, MBA, Named President & CEO Of Renown Health

Lanzada en asociación con el Desert Research Institute, una nueva investigación del proyecto Healthy Nevada Project® determina que un diagnóstico confirmado no siempre produce cambios en el cuidado del paciente. El hecho de entregar a las personas información de salud que pueda cambiar sus vidas no garantiza que las personas, o sus proveedores de atención médica, actuarán en consecuencia. La educación de seguimiento y las conversaciones sobre los planes de cuidado ejecutables con los pacientes y sus médicos son los próximos pasos clave, de acuerdo con la nueva investigación del Healthy Nevada Project. El Healthy Nevada Project es un proyecto de investigación y detección genética que se lanzó en 2016 como una asociación entre DRI y Renown Health. El proyecto ahora tiene más de 50,000 participantes y cuenta con secuenciación genética proporcionada por Helix. Entre septiembre de 2018 y septiembre de 2020, el Healthy Nevada Project notificó exitosamente a 293 participantes que estaban genéticamente en riesgo de desarrollar cáncer de pecho y ovario, síndrome de Lynch o hipercolesterolemia familiar hereditarios, tres afecciones genéticas comunes conocidas colectivamente como afecciones de Nivel 1 de los Centros para el Control y la Prevención de Enfermedades (Centers for Disease Control and Prevention, CDC). En un estudio publicado hoy en Frontiers in Genetics, los científicos del Healthy Nevada Project analizaron qué impacto tuvo el hecho de notificar a un paciente sobre un resultado positivo para una condición de Nivel 1 de los CDC en el cuidado que recibió el paciente en los meses y años posteriores. Según sus resultados, entre los 293 participantes del Healthy Nevada Project que fueron notificados del riesgo genético de desarrollar una afección del Nivel 1 de los CDC, el 71 % de participantes con registros médicos electrónicos compartieron sus hallazgos con los proveedores de atención médica. Sin embargo, solo el 30 % de los registros médicos electrónicos de estos pacientes contenía documentación del diagnóstico genético, y solo el 10 % de los pacientes examinados experimentó un posible cambio en el cuidado después de recibir los resultados de su examen de detección genético. “El Healthy Nevada Project se implementó con un enfoque ‘sin intervención’ en el que los participantes reciben sus hallazgos y deciden con quiénes y cuándo desean compartirlos. Los hallazgos no se agregaron automáticamente a sus registros médicos electrónicos”, explicó el Dr. Gai Elhanan, científico de datos médicos en DRI y coautor del estudio. “Lo que estamos aprendiendo ahora es que para garantizar que los hallazgos genéticos importantes se integren en el régimen de cuidado, es importante que su incorporación en los registros médicos electrónicos forme parte del estudio”. Este estudio se basa en investigaciones anteriores del Healthy Nevada Project publicadas en Nature Medicine. En ellas se demuestra la importancia de realizar exámenes de detección para las afecciones del Nivel 1 de los CDC, las cuales afectan a aproximadamente a 1 de cada 75 personas y se pueden mitigar e incluso se puede evitar que se conviertan en enfermedades cuando se detectan en forma temprana. Este estudio determinó que hasta el 90 % de los casos con afecciones del Nivel 1 de los CDC no son detectados por los proveedores clínicos en las evaluaciones y los exámenes de detección que se realizan durante las visitas de cuidado clínico habitual. Durante el estudio actual, los científicos del Healthy Nevada Project descubrieron que el 19 % de participantes estudiados ya había desarrollado una de las afecciones del Nivel 1 de los CDC y, por lo tanto, podrían haberse beneficiado de una notificación más temprana sobre su afección. El equipo del estudio espera que sus hallazgos estimulen a los residentes de Nevada a obtener pruebas genéticas para estas afecciones relativamente comunes. Incluso si las personas son mayores o ya han sufrido enfermedades relacionadas con estas afecciones, las pruebas también podrían ser beneficiosas para los hermanos, los niños y los nietos que también pueden estar en riesgo y que posteriormente podrían someterse a exámenes de detección en caso de un hallazgo positivo. El equipo del estudio también incita a informar a los proveedores de atención médica sobre la importancia de incorporar diagnósticos genéticos en las recomendaciones farmacéuticas (por ejemplo, para la hipercolesterolemia familiar) y de tratamiento a los pacientes. “Como resultado de este análisis, los médicos de Renown Health y los investigadores del Healthy Nevada Project han logrado cambios significativos, lo que incluye la obtención del consentimiento informado de los participantes para incorporar hallazgos positivos de sus informes genéticos directamente en su registro médico electrónico”, explicó Daniel Kiser, M.S., científico auxiliar de investigación de ciencia de datos en DRI y coautor del estudio. “Esto ayudará tanto a los participantes como a sus proveedores de cuidado clínico, y a todo el estado a maximizar los beneficios a largo plazo de los exámenes de detección genéticos voluntarios basados en la población del Healthy Nevada Project”. Información adicional: El texto completo del estudio, Incomplete Penetrance of Population-Based Genetic Screening Results in Electronic Health Record, está disponible en Frontiers in Genetics: https://www.frontiersin.org/articles/10.3389/fgene.2022.866169/full?&utm_source=Email_to_authors_&utm_medium=Email&utm_content=T1_11.5e1_author&utm_campaign=Email_publication&field=&journalName=Frontiers_in_Genetics&id=866169. Este proyecto fue financiado por Renown Health, fundación de Renown Health y la Oficina de Desarrollo Económico del Gobernador de Nevada. Entre los autores del estudio se incluyen Gai Elhanan (DRI), Daniel Kiser (DRI), Iva Neveux (DRI), Shaun Dabe (Renown Health), Alexander Bolze (Helix), William Metcalf (DRI), James Lu (Helix) y Joseph Grzymski (DRI/Renown Health). Para obtener más información sobre el Healthy Nevada Project® o para solicitar un examen de detección genético, visite: https://healthynv.org/ Acerca del DRI El Desert Research Institute (DRI) es un reconocido líder mundial en investigación ambiental básica y aplicada. Comprometidos con la excelencia e integridad científicas, el cuerpo docente del DRI, los estudiantes que trabajan juntos y el personal han desarrollado conocimientos científicos y tecnologías innovadoras en proyectos de investigación en todo el mundo. Desde 1959, la investigación de DRI ha profundizado el conocimiento científico sobre temas que van desde el impacto de los seres humanos en el medioambiente hasta el impacto del medioambiente en los seres humanos. Los hallazgos científicos impactantes y las soluciones inspiradoras del DRI apoyan la economía diversa de Nevada, proporcionan oportunidades educativas basadas en la ciencia e informan a legisladores, líderes empresariales y miembros de la comunidad. El DRI tiene campus en Las Vegas y Reno y funciona como el grupo de investigación sin fines de lucro del Sistema de Educación Superior de Nevada. Para obtener más información, visite www.dri.edu. Acerca de Renown Health Renown Health es la red de atención médica integrada de administración local y sin fines de lucro más grande de la región, que presta servicios a Nevada, Lake Tahoe y el noreste de California. Con una fuerza laboral diversa de más de 7,000 empleados, Renown ha fomentado una cultura de excelencia, determinación e innovación de larga data. La organización se compone de un centro de urgencias, dos hospitales de cuidados agudos, un hospital infantil, un hospital de rehabilitación, un grupo médico y una red de atención de urgencias y Hometown Health, la compañía de seguros sin fines de lucro más grande de la región y de propiedad local, Hometown Health. Actualmente, Renown está inscribiendo participantes en el estudio genético de salud poblacional basado en la comunidad más grande del mundo, el Healthy Nevada Project®. Visite renown.org para obtener más información. Acerca de Helix Helix es la compañía líder en genómica y vigilancia viral de la población cuyas operaciones se basan en el cuidado clínico, la investigación y el análisis de datos. Helix permite que los sistemas de salud, las empresas de ciencias biológicas, los pagadores y los socios gubernamentales aceleren la integración de los datos genómicos en el cuidado médico del paciente y en la toma de decisiones de salud pública. Obtenga más información en www.helix.com.

Leer más About Un estudio demuestra la importancia de garantizar el seguimiento del participante y del proveedor después de obtener el resultado de un examen de detección genético

Thomas Graf, médico ejecutivo con experiencia, nombrado director interino hoy El Consejo de Administración de Renown Health, dirigido por Adam Kramer, anunció que el mandato del Dr. Tony Slonim como presidente y director ejecutivo de Renown Health ha finalizado. Thomas R. Graf, M.D., FAAFP, ocupará el cargo de director ejecutivo interino. El Dr. Graf asumirá el cargo y la autoridad del director ejecutivo además de su función actual de director clínico y de calidad en Renown y de decano asociado sénior de Asuntos Clínicos en la Facultad de Medicina de Reno de la University of Nevada. Sy Johnson, MBA, actual director de operaciones de Renown, ha sido ascendido a presidente y director de operaciones interino. Tras la finalización de una investigación exhaustiva de las inquietudes planteadas a la Junta Directiva, la Junta determinó que Renown Health, sus pacientes y el personal necesitaban un nuevo liderazgo. En consecuencia, el Dr. Slonim ha sido despedido con causa de su puesto como director ejecutivo de Renown Health. El Sr. Kramer anunció hoy la transición con las siguientes palabras: “se necesitan una nueva dirección y un nuevo liderazgo dado el trabajo crítico que hay por delante. Tengo plena fe en el Dr. Tom Graf y en Sy Johnson, y en sus equipos de liderazgo sénior, quienes ya supervisan las operaciones del sistema de atención médica y quienes ayudarán a garantizar una transición sin problemas”. El Dr. Graf trabajará en colaboración con Sy Johnson, MBA, presidente interino y director de operaciones, y un equipo experimentado de ejecutivos de atención médica para guiar a Renown hacia el alcance de sus objetivos estratégicos y operativos. Kramer agregó: “Durante más de 160 años, Renown ha proporcionado atención médica asequible, accesible y de la más alta calidad a nuestra comunidad. Este compromiso continúa en pie mientras nuestros 7,000 héroes de la atención médica siguen haciendo lo más importante y lo que mejor hacemos: cuidar de nuestra comunidad”. El Dr. Graf continuará impulsando la transformación de Renown para ser una organización de atención basada en el valor, ayudará a promover las tecnologías para mejorar la experiencia del paciente y colaborará con los proveedores del Renown Medical Group, los hospitales de cuidados intensivos y mediante la red clínicamente integrada de Western Clinical Alliance, una organización de atención responsable, y la afiliación con la UNR Med. Graf es un médico ejecutivo muy exitoso que ha liderado organizaciones de atención médica y compañías aseguradoras, como también una firma de consultoría nacional. El Dr. Graf, médico de medicina de familia, investigador y académico, se ha centrado en impulsar mejoras de calidad para reducir el costo total de la atención. Ha desarrollado y hecho publicaciones sobre modelos de atención que han logrado resultados mensurablemente mejores en cuanto a calidad, costo y experiencia en una variedad de centros. Ha ejercido en un sistema de prestación de servicios integrado, por más de una década en Geisinger (PA), así como en redes clínicamente integradas y en organizaciones de atención responsable. También ha trabajado con varios centros médicos académicos en el área de consultoría con The Chartis Group. El Dr. Graf agrega: “Mi objetivo es generar mayor valor para el paciente al brindarle atención de la más alta calidad clínica. Renown es reconocido a nivel nacional por brindar una excelente atención mediante el empleo de enfoques creativos, innovadores y que aprovechan al máximo la tecnología, y espero con ansias integrar a médicos y administradores en un plan que respalde esta visión. Estoy agradecido por la oportunidad de contribuir al gran progreso que Renown Health está haciendo para convertirse en el mejor lugar donde ejercer la medicina y recibir atención. Me entusiasma unirme a este camino de transformación hacia una atención basada en el valor y servir a los pacientes, médicos y a nuestra comunidad”. Sy Johnson ha dirigido las operaciones de la red y el hospital de Renown Health durante casi siete años, más recientemente como jefe de personal/director de operaciones y anteriormente como vicepresidente ejecutivo y director de operaciones de Renown. Antes de unirse a Renown, el Sr. Johnson se desempeñó como director ejecutivo, vicepresidente sénior y director financiero de Peace Health en Vancouver, Washington, y fue parte de la gerencia sénior de Arthur Andersen & Co y KPMG. Acerca de Renown Health Renown Health es la red de atención médica integrada de administración local y sin fines de lucro más grande de la región, que presta servicios a Nevada, Lake Tahoe y el noreste de California. Con una fuerza laboral diversa de más de 7,000 empleados, Renown ha fomentado una cultura de excelencia, determinación e innovación de larga data. La organización se compone de un centro de urgencias, dos hospitales de cuidados agudos, un hospital infantil, un hospital de rehabilitación, un grupo médico y una red de atención de urgencias y Hometown Health, la compañía de seguros sin fines de lucro más grande de la región y de propiedad local, Hometown Health. Actualmente, Renown está inscribiendo participantes en el estudio genético de salud poblacional basado en la comunidad más grande del mundo, el Healthy Nevada Project®. Visite renown.org para obtener más información.

Leer más About La Junta de Renown Health anuncia transición de director ejecutivo

Renown es reconocido por usar tecnología avanzada para mejorar la salud y la atención en la comunidad El Colegio de Ejecutivos de Gestión de la Información Médica (College of Healthcare Information Management Executives, CHIME) anunció que Renown Health ha obtenido el reconocimiento “CHIME Digital Health Most Wired 2021” como proveedor certificado de servicios agudos de nivel 7 y de atención ambulatoria de nivel 7. The CHIME Digital Health Most Wired program conducts an annual survey to assess how effectively healthcare organizations apply technology to improve health and care in their communities.  Renown Health was the only health care system in Nevada to make this year’s list, ranking alongside other national health leaders including UCLA Health, Scripps, Sharp, Stanford, Geisinger, Johns Hopkins, Yale New Haven and Intermountain Health.  “We are proud of our national reputation as an innovator in implementing new technology and systems of care to improve the health of our patients and the community,” said Tony Slonim, MD, D.Ph., President & CEO. “With our incredible IT team and partners, we are transforming care and demonstrating value in a way that appeals to patients and helps clinicians improve outcomes and reduce costs. Through Renown’s technology, thousands of people a day now choose the physician that’s best for them at renown.org; have an online video visit with their doctor from their laptop; self-schedule a mammogram or refill medications through the MyChart app; book ahead for an Urgent Care visit, and may receive hospital-level clinical monitoring in the comfort of their own homes through the Renown Transfer and Operations Center.” “La transformación digital en la atención médica se ha acelerado a un nivel sin precedentes desde 2020, y los próximos años traerán una ola de innovación que empoderará a los consumidores de atención médica y asombrará a la industria”, dijo Russell P. Branzell, presidente y director ejecutivo de CHIME. “The Digital Health Most Wired program recognizes the outstanding digital leaders who have paved the way for this imminent revolution in healthcare. Renown’s trailblazing commitment to rapid transformation has set an example for the entire industry in how to pursue a leadership vision with determination, brilliant planning and courage to overcome all challenges.”  Speaking on the Wall St. Journal podcast, The Journal on Friday, Dr. Slonim described how Renown Health is one of the first institutions in the nation to provide hospital-at-home technology. Mediante el nuevo Renown Transfer and Operations Center, los médicos, enfermeros y coordinadores de atención pueden monitorear a más de 1,000 pacientes hospitalizados y pacientes en estados menos agudos en sus hogares, lo que hace que la atención sea más asequible y conveniente. “Este centro de vanguardia ayuda a garantizar una atención eficiente para los pacientes y proveedores de todo el norte de Nevada, Lake Tahoe y el noreste de California”, dijo Sy Johnsonn, jefe de personal de Renown. “Through this highly coordinated care logistics system, Renown is now able to deliver the right care, at the right time and place across the integrated delivery system. This system is enabling providers to provide care closer to home, in lower-cost ambulatory, outpatient surgical and skilled nursing settings- instead of the hospital, and to deliver a sizeable portion of care to patients- where they want to be- in their homes.” Bernard, a remote-home monitoring patient, provides a Thank You and Congratulations to the Renown team in a video here.  “Our teams are excited to partner with clinicians to adopt technologies that improve the delivery of care, across the entire Renown Health enterprise,” said Chuck Podesta, Chief Information Officer. “We have optimized clinical workflows so that our clinicians receive timely alerts and can quickly respond to patient needs. As a team, we are honored to receive this prestigious award for technology that enables us to provide safer, more effective and more efficient care for patients and our community.” Además, el sitio web de Renown ahora es uno de los más avanzados en el país, con más de 2.2 millones de visitantes durante el último año. Renown también obtuvo siete estrellas, la calificación más alta que existe, por el uso del sistema de registro médico electrónico Epic. Un total de 36,674 organizaciones estuvieron representadas en el programa 2021 Digital Health Most Wired. The surveys assessed the adoption, integration and impact of technologies in healthcare organizations at all stages of development, from early development to industry leading.     About CHIME The College of Healthcare Information Management Executives (CHIME) is an executive organization dedicated to serving chief information officers (CIOs), chief medical information officers (CMIOs), chief nursing information officers (CNIOs), chief innovation officers (CIOs), chief digital officers (CDOs) and other senior healthcare IT leaders. Con casi 3,400 miembros en 55 países y más de 150 socios comerciales de TI de atención médica y firmas de servicios profesionales, CHIME proporciona un entorno altamente interactivo y confiable que permite a los líderes profesionales sénior y de la industria colaborar, intercambiar mejores prácticas, abordar las necesidades de desarrollo profesional y defender el uso eficaz de la gestión de la información para mejorar la salud y la atención en las comunidades a las que sirven. For more information, please visit chimecentral.org. Acerca de Renown Health Renown Health es una red de atención médica integrada de administración local y sin fines de lucro que brinda servicios al norte de Nevada, Lake Tahoe y el noreste de California. En los rankings de mejores hospitales de U.S. News y World Report, Renown Regional Medical Center ocupa el primer puesto en el estado de Nevada. Renown tiene una larga trayectoria y un compromiso de larga data con la mejora de la atención y la salud de nuestra comunidad. Actualmente, Renown está inscribiendo participantes en el estudio genético de salud poblacional basado en la comunidad más grande del mundo, el Healthy Nevada Project®. Visite renown.org para obtener más información.

Leer más About Renown Health encabeza la lista “Most Wired” 2021 por Innovación Digital, Tecnología y Mejor Experiencia del Paciente

Juntos, realizarán pruebas a más de 30,000 participantes del estudio elegibles antes de 2023 para determinar el riesgo de cirrosis y enfermedades relacionadas con el hígado. Renown Institute for Health Innovation (IHI) announced today that the organization and Gilead Sciences, Inc. will be joining forces with Siemens Healthineers to offer the Enhanced Liver Fibrosis (ELF™) Test to people with risks for nonalcoholic steatohepatitis (NASH) enrolled in the Healthy Nevada Project (HNP). The ELF Test will help identify people most at risk for progressing to cirrhosis and liver-related outcomes and allow healthcare providers to intervene before irreparable damage occurs. This noninvasive blood test uses three serum biomarkers to create an ELF score from a predefined algorithm, which can be used by doctors to help evaluate if a patient requires increased medical care and monitoring for their condition. La enfermedad de hígado graso no alcohólico (EHGNA), que incluye la EHNA, es frecuente en Nevada y está subdiagnosticada, y probablemente afecte a más de 500,000 adultos en nuestro estado. If undetected and untreated, NASH can result in liver cirrhosis and may require liver transplantation or lead to death. Hay más de 12,000 personas en la lista de espera para trasplante de hígado en los EE. UU. y esta cifra continúa aumentando debido al incremento en la prevalencia de la EHGNA. “Thanks to important data collected through our Nonalcoholic Steatohepatitis Liver Disease Genome Atlas study, we now know that NASH is prevalent in the state of Nevada,” said Tony Slonim, M.D., DrPH, FACHE, president and CEO of Renown Health. “We are proud to expand our partnership with Gilead and begin working with Siemens Healthineers to improve health of those with liver disease and to take early detection one step further by offering Enhanced Liver Fibrosis, ELF testing for patients of Renown Health. This test provides our team of highly-skilled physicians an advanced, noninvasive method to actively assess dynamic liver fibrosis in study participants and intervene whenever necessary, contributing to a healthier Nevada.”  “Gilead believes that noninvasive tests, including the ELF Test, will help improve the experience of people living with NASH. These tests may help to diagnose liver disease, monitor disease progression and evaluate responses to treatment without the requirement for liver biopsy,” said Rob Myers, MD, Vice President, Liver Fibrosis Clinical Research at Gilead Sciences. “The ELF Test has proven itself to be a valuable tool in NASH management and we hope this partnership will further support its use in routine care.”  “We are very pleased that NASH patients in the Healthy Nevada Project now have access to the ELF Test which offers clinically useful prognostic information for their condition with the convenience of a simple blood test. Using our advanced laboratory expertise together with Renown IHI and Gilead, we can work towards better understanding of NASH and liver disease in a representative patient population,” said Sebastian Kronmueller, Head of Molecular Diagnostics at Siemens Healthineers. “We launched the Healthy Nevada Project to help people understand more about their health, to identify serious health risks, and to give people access to innovations like the ELF Test, so they can live their best lives,” said Renown’s chief scientific officer, Dr. Joseph Grzymski, who is also a research professor at the Desert Research Institute and principal investigator of the Healthy Nevada Project. Es increíblemente gratificante poder informar hallazgos clínicos para ayudar a nuestros 50,000 participantes voluntarios del estudio y asistir a los proveedores de atención médica a ayudar a sus pacientes”. La provisión de la prueba de ELF se basa en una colaboración estratégica anunciada previamente entre el Renown IHI y Gilead en julio de 2019. Esta sociedad en curso tiene como objetivo recopilar y analizar datos de salud genéticos y electrónicos anónimos de 60,000 participantes del estudio elegibles con el fin de mejorar la comprensión de la EHGNA y la EHNA y para potencialmente orientar el desarrollo de opciones de tratamiento para estas enfermedades. Acerca de la EHGNA y la EHNA La EHGNA es una acumulación de grasa en el hígado en personas que no tienen antecedentes de abuso de alcohol. Es normal que el hígado contenga algo de grasa, pero si más del 5 por ciento del contenido hepático es grasa, se considera hígado graso (esteatosis). NASH is the most severe form of NAFLD in which a person has liver cell damage and inflammation of the liver. Inflammation and liver cell damage can cause fibrosis, or scarring of the liver, and can cause decreased liver function (1). The symptoms of NASH are often silent or non-specific, making it difficult to diagnose. Aproximadamente, un tercio de las personas con EHNA desarrollan cirrosis o daño hepático irreversible (2). About the ELF™ Test The ELF Test is a noninvasive blood test that can quickly identify which patients are at an elevated risk for developing cirrhosis and other liver-related clinical events (LREs). In contrast to standard liver enzyme tests that reflect liver damage that has already occurred, the ELF Test combines three serum direct biomarkers of active fibrosis. The ELF Test algorithm measures each of these biomarkers to create an ELF score, which can be used as an aid to assess the risk for future disease progression. Doctors may use this ELF score to help evaluate if a patient requires increased medical care and monitoring for their condition. Individuals interested in determining their risk for NASH and its progression are encouraged to enroll in the Nonalcoholic Steatohepatitis Liver Disease Genome Atlas study. Those who have already consented and participated in the study will be contacted with more information on how to receive an ELF blood test. Para obtener más información o para inscribirse, comuníquese a la casilla de correo RenownIHI@renown.org o al teléfono (775) 982-6914. The Enhanced Liver Fibrosis (ELF™) Test kit is not available for sale in the U.S. Product availability may vary from country to country and is subject to varying regulatory requirements.  In the U.S., the ELF Testing Service is available from Siemens Healthcare Laboratory, LLC (SHL), a CLIA-certified laboratory located in Berkeley, Calif. The ELF Testing Service, including the establishment of performance characteristics, was developed by SHL. The ELF Test has not been cleared or approved by the U.S. Food and Drug Administration. SHL is regulated under CLIA as qualified to perform high complexity testing. The ELF Test is used for clinical purposes and should not be regarded as investigational use only or research use only. About Renown Health Renown Health is the region’s largest, locally owned and governed, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. Con una fuerza laboral diversa de más de 7,000 empleados, Renown ha fomentado una cultura de excelencia, determinación e innovación de larga data. La organización se compone de un centro de urgencias, dos hospitales de cuidados agudos, un hospital infantil, un hospital de rehabilitación, un grupo médico y una red de atención de urgencias y Hometown Health, la compañía de seguros sin fines de lucro más grande de la región y de propiedad local, Hometown Health. Renown’s institute model addresses social determinants of health and includes: Child Health, Behavioral Health & Addiction, Healthy Aging and Health Innovation. Clinical institutes include: Cancer, Heart and Vascular Health, Neurosciences and Robotic Surgery. Actualmente, Renown está inscribiendo participantes en el estudio genético de salud poblacional basado en la comunidad más grande del mundo, el Healthy Nevada Project®. For more information visit, renown.org. About the Renown Institute for Health Innovation Renown Institute for Health Innovation is a collaboration between Renown Health - a locally governed and locally owned, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California; and the Desert Research Institute - a recognized world leader in investigating the effects of natural and human-induced environmental change and advancing technologies aimed at assessing a changing planet. Renown IHI research teams are focused on integrating personal healthcare and environmental data with socioeconomic determinants to help Nevada address some of its most complex environmental health problems; while simultaneously expanding the state’s access to leading-edge clinical trials and fostering new connections with biotechnology and pharmaceutical companies. Learn more at healthynv.org. Renown Health es la red de atención médica más completa e integrada de Nevada y mantiene registros médicos electrónicos para 1.02 millones de pacientes registrados. En 2016, Renown Health y el Desert Research Institute crearon el Healthy Nevada Project (HNP), el primer estudio de salud poblacional basado en la comunidad del país. En 2017, el HNP comenzó una sociedad con Helix para aprovechar sus servicios de salud poblacional, la secuenciación Exome+™ y las herramientas de participación del consumidor. The HNP is now an ongoing collaboration between Renown IHI, the Desert Research Institute, a global leader in environmental data and applied research, and Helix, a personal genomics company. HNP combines genetic, environmental, social and clinical data to address individual and community health needs with the goal of improving health across the state and the nation. El HNP actualmente tiene más de 60,000 participantes. For more information, visit healthynv.org.  About Siemens Healthineers Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) is shaping the future of Healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalizing healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostic, image-guided therapy, and in-vivo diagnostics. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers ability to provide high-quality, efficient care to patients. En el año fiscal 2020, que finalizó el 30 de septiembre de 2020, Siemens Healthineers, que tiene aproximadamente 54,000 empleados en todo el mundo, generó ingresos por €14.5 mil millones y un EBIT ajustado de €2.2 mil millones. Encontrará más información disponible en www.siemens-healthineers.com.Media Contacto de Siemens Healthineers: Lance LongwellM: 610-448-6341E: lance.longwell@siemens-healthineers.com

Leer más About Renown Institute Expands Partnership to Offer ELF Testing

The Healthy NV Project® launches a new study to identify how private well water could impact the health of those living in the household. You use your faucet to wash your hands, make coffee and fill your water bottle. Sin embargo, para las aproximadamente 41,000 personas en los condados de Washoe y Churchill que dependen de agua de pozos privados, es posible que el H2O contenga contaminantes no detectados que podrían estar afectando su salud. The Healthy Nevada Project®, with support from the National Institutes of Health (NIH), is launching a new study to discover how private well water quality impacts the health of well owners. By providing free water testing kits to interested Healthy Nevada Project® participants, researchers will collect samples and give results back to well owners, along with resources for potential treatment options. Data from previous studies in Nevada show elevated concentrations of heavy metals in some private, household wells. Since water from household wells is not monitored for quality by government agencies, well water testing helps ensure water does not contain dangerous levels of heavy metals, such as lead, which can lead to adverse health impacts.  Those with a household well interested in receiving a free water testing kit must be enrolled in the Healthy Nevada Project’s population genetic screening study and consent to be a part of further research. People interested in joining the study can simply sign up to receive a genetic spit test kit in the mail or join the waitlist to be notified when in-person testing resumes. “The goals of the Healthy Nevada project are to improve population health and better understand processes that increase disease risks, such as cancer. In this study, we engage with our study participants and inform them about the impact of the environment on their health, while researching environmental contaminants that may elevate cancer risk,” said Joseph Grzymski, Ph.D., research professor at DRI, principal investigator of the Healthy Nevada Project® and chief scientific officer for Renown Health. “En un tiempo en el que las personas pasan más tiempo en casa, nos complace lanzar este estudio multidisciplinario que indaga en los posibles impactos en la salud que puede tener la fuente de agua de un hogar”. “Mientras el Healthy Nevada Project continúa sirviendo a más de 54,000 voluntarios de investigación, nos enorgullece proporcionar información útil a los participantes para que puedan hacer mejoras transformadoras en su entorno doméstico”, dijo Tony Slonim, D.M., DrPH, FACHE, presidente y director ejecutivo de Renown Health y codirector del Healthy Nevada Project. “This allows every person with well water in Nevada, to have important information, at no charge, to help live healthier and better lives and to protect their family’s health.” The Healthy Nevada Project® is the fastest-enrolling genetic study in the country. The Project is also the first of its kind to return clinical results to study volunteers, which means participants can learn their genetic risks tied to heart disease and certain cancers, as well as lifestyle changes that could potentially help reduce their risk and prevent disease. To enroll in the Healthy Nevada Project, please visit healthynv.org.      Renown Institute for Health Innovation is a collaboration between Renown Health - a locally governed and locally owned, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California; and the Desert Research Institute - a recognized world leader in investigating the effects of natural and human-induced environmental change and advancing technologies aimed at assessing a changing planet. Renown IHI research teams are focused on integrating personal healthcare and environmental data with socioeconomic determinants to help Nevada address some of its most complex environmental health problems; while simultaneously expanding the state’s access to leading-edge clinical trials and fostering new connections with biotechnology and pharmaceutical companies. Learn more at healthynv.org.

Leer más About ¿Podría el agua de pozos privados ofrecer información sobre la salud?

Gilead Sciences, Inc. (Nasdaq: GILD) and the Renown Institute for Health Innovation (IHI) today announced a strategic collaboration to collect and analyze genetic and electronic health data that can enhance the understanding of nonalcoholic steatohepatitis (NASH) and potentially inform development of treatment options for the disease. En virtud de los términos del acuerdo de colaboración y licencia, Gilead proporcionará fondos al Renown IHI para secuenciar y analizar el ADN de 15,000 personas que viven con EHNA o con enfermedad de hígado graso no alcohólico (EHGNA), así como de una cohorte de control de 40,000 personas en el estado de Nevada. “Combining the sequencing of protein coding DNA, with extensive electronic health record data will enable a deep analysis of the roles of genetics and environment in NASH incidence and progression,” said John McHutchison, AO, MD, Chief Scientific Officer and Head of Research and Development, Gilead Sciences. “The analysis of these large datasets in collaboration with Renown IHI could help identify genetic variants that impact the risk of developing NASH and thereby advance the discovery and development of new treatments for this disease.” Renown Health es la red de atención médica más completa e integrada de Nevada y mantiene registros médicos electrónicos para 1.02 millones de pacientes registrados. En 2016, Renown Health y el Desert Research Institute crearon el Healthy Nevada Project (HNP), el primer estudio de salud poblacional basado en la comunidad del país. En 2017, el HNP comenzó una sociedad con Helix para aprovechar sus servicios de salud poblacional, la secuenciación Exome+™ y las herramientas de participación del consumidor. The HNP is now an ongoing collaboration between Renown IHI, the Desert Research Institute, a global leader in environmental data and applied research, and Helix, a personal genomics company. HNP combines genetic, environmental, social and clinical data to address individual and community health needs with the goal of improving health across the state and the nation. El HNP actualmente tiene 40,000 participantes. “Combining genetic sequencing with large sets of data can play a critical role in understanding and identifying serious health risks, including diseases like NASH. We are excited to collaborate with Gilead to better understand the condition and its complexities,” said Anthony Slonim, MD., DrPH. “Any genetic variants identified in participants through the collaboration may be shared with the participants for patient care purposes.”     About NASH Nonalcoholic steatohepatitis (NASH) is a chronic form of liver disease characterized by excess fat in the liver, inflammation, and liver cell damage. Inflammation and liver cell damage can cause scarring of the liver, or fibrosis, and ultimately lead to cirrhosis or liver cancer. La EHNA es más frecuente en personas con ciertas afecciones, que incluyen obesidad y diabetes tipo 2. There are currently limited approved treatments for patients living with NASH.   About Gilead Sciences Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead opera en más de 35 países alrededor del mundo, con sede central en Foster City, California. Para obtener más información sobre Gilead Sciences, visite el sitio web de la empresa en www.gilead.com.   About Renown Health Renown Health is a locally governed and locally owned, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. Renown es uno de los mayores empleadores privados de la región y cuenta con una fuerza laboral de más de 7,000. It comprises three acute care hospitals, a rehabilitation hospital, the area’s most comprehensive medical group and urgent care network, and the region’s largest and only locally owned not-for-profit insurance company, Hometown Health. Renown Health’s commitment has extended beyond traditional health care to include community health and well-being. Renown Health works to improve health care through science, research and genetics; forge community partnerships that improve lives and develop innovative models that are improving health care in Nevada. For more information, visit renown.org.    About Helix Helix’s mission is to empower every person to improve their life through DNA. Helix is accelerating the integration of genomic data into clinical care and broadening the impact of large-scale population health programs by providing comprehensive expertise in DNA sequencing, bioinformatics, and individual engagement. Mediante el uso de su ensayo Exome+™ de propiedad exclusiva, un exoma de tipo panel mejorado con más de 300,000 regiones no codificantes informativas, Helix ofrece a los sistemas de salud una solución escalable que permite el descubrimiento de información genética médicamente relevante y que potencialmente puede salvar vidas. Additionally, Helix offers a suite of DNA-powered products for continued individual engagement and discovery. Helix is headquartered in the San Francisco Bay Area and has one of the world’s largest CLIA-certified, CAP-accredited Next Generation Sequencing labs, located in San Diego, California. Obtenga más información en www.helix.com. Helix, the Helix logo, and Exome+ are trademarks of Helix Opco, LLC.   Gilead Forward-Looking Statement This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the risk that the parties may not realize the potential benefits of this collaboration, and Gilead may fail to discover, develop and commercialize any product candidates for the treatment of NASH. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. Estos y otros riesgos se describen en detalle en el Informe Trimestral de Gilead en el Formulario 10-Q para el trimestre que finalizó el 31 de marzo de 2019, presentado ante la Comisión de Bolsa y Valores de los EE. UU. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.   Additional Media Contact: Sung Lee, Investors                                                                                                                                                        650-524-7792 Arran Attridge, Media                                                                                                                                                        650-425-8975

Leer más About Gilead Sciences y el Renown Institute for Health Innovation anuncian una colaboración estratégica para promover la comprensión de la esteatohepatitis no alcohólica (EHNA)